Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunovia AB ( (SE:IMMNOV) ) has provided an announcement.
Immunovia AB announced that October 16, 2025, marks the last day for trading subscription rights in its rights issue, which aims to issue up to 333,908,814 shares to raise approximately SEK 100 million. The rights issue, fully covered by commitments, is part of the company’s strategy to strengthen its financial position and support its operations in the pancreatic cancer diagnostic market.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes blood-based tests to detect proteins and antibodies indicative of pancreatic cancer, particularly targeting high-risk individuals. Immunovia collaborates with healthcare providers, experts, and patient advocacy groups to make its tests accessible, with the USA being its largest market.
Average Trading Volume: 13,972,300
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK211.2M
Find detailed analytics on IMMNOV stock on TipRanks’ Stock Analysis page.